TY - JOUR
T1 - Low proliferative rate of invasive node-negative breast cancer predicts for a favorable outcome
T2 - a prospective evaluation of 669 patients.
AU - Jones, S.
AU - Clark, G.
AU - Koleszar, S.
AU - Ethington, G.
AU - Mennel, R.
AU - Paulson, S.
AU - Brooks, B.
AU - Kerr, R.
AU - Denham, C.
AU - Savin, M.
AU - White, C.
AU - Blum, J.
AU - Kirby, R.
AU - Stone, M.
AU - Pippen, J.
AU - Kitchens, L.
AU - George, T.
AU - Cooper, B.
AU - Peters, G.
AU - Knox, S.
AU - Grant, M.
AU - Cheek, H.
AU - Jones, R.
AU - Kuhn, J.
AU - Lieberman, Z.
AU - Savino, D.
AU - Rietz, C.
N1 - Funding Information:
This work was generously supported by funds from the Wayne Foundation, Dallas, Texas, and was presented at the 35th American Society of Clinical Oncology meeting, Atlanta, Georgia, on May 16, 1999. Our deepest thanks go to Helen McCracken for her help with manuscript preparation.
PY - 2001/1
Y1 - 2001/1
N2 - This study was designed to compare outcome in terms of disease-free survival (DFS) in women with histologically negative axillary lymph nodes and documented low proliferative rate cancer to other well-defined prognostic factors including type of adjuvant treatment. Between 1988 and 1998, we studied 669 patients with invasive node-negative breast cancer up to 5 cm in size and low proliferative rate measured by flow cytometry to determine S-phase fraction (SPF) or by histochemistry (Ki67/MIB1). At a median follow-up of 53 months, 5-year DFS for the entire group was 94% and did not differ significantly by type of systemic adjuvant treatment: none (133 patients, 95% DFS), tamoxifen (441 patients, 94% DFS), or chemotherapy with doxorubicin and cyclophosphamide (95 patients, 92% DFS). In a multivariate prognostic factor analysis, only tumor size was significant; 5-year DFS was 96% for T1N0 cancer versus 89% for T2N0 cancer (P = 0.01). We have prospectively confirmed that a low rate of proliferation as measured by SPF or MIB1 determination confers an excellent prognosis in invasive node-negative breast cancer up to 5 cm in size, regardless of adjuvant treatment.
AB - This study was designed to compare outcome in terms of disease-free survival (DFS) in women with histologically negative axillary lymph nodes and documented low proliferative rate cancer to other well-defined prognostic factors including type of adjuvant treatment. Between 1988 and 1998, we studied 669 patients with invasive node-negative breast cancer up to 5 cm in size and low proliferative rate measured by flow cytometry to determine S-phase fraction (SPF) or by histochemistry (Ki67/MIB1). At a median follow-up of 53 months, 5-year DFS for the entire group was 94% and did not differ significantly by type of systemic adjuvant treatment: none (133 patients, 95% DFS), tamoxifen (441 patients, 94% DFS), or chemotherapy with doxorubicin and cyclophosphamide (95 patients, 92% DFS). In a multivariate prognostic factor analysis, only tumor size was significant; 5-year DFS was 96% for T1N0 cancer versus 89% for T2N0 cancer (P = 0.01). We have prospectively confirmed that a low rate of proliferation as measured by SPF or MIB1 determination confers an excellent prognosis in invasive node-negative breast cancer up to 5 cm in size, regardless of adjuvant treatment.
UR - http://www.scopus.com/inward/record.url?scp=0035240070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035240070&partnerID=8YFLogxK
U2 - 10.3816/cbc.2001.n.005
DO - 10.3816/cbc.2001.n.005
M3 - Article
C2 - 11899353
AN - SCOPUS:0035240070
SN - 1526-8209
VL - 1
SP - 310-314; discussion 315-317
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 4
ER -